Items where authors include "Blauvelt, A."

Article

Haag, C., Alexis, A., Aoki, V. et al. (28 more authors) (2025) A practical guide to using oral JAK inhibitors for atopic dermatitis from the International Eczema Council. British Journal of Dermatology, 192 (1). pp. 135-143. ISSN 0007-0963

Deodhar, A., Blauvelt, A., Lebwohl, M. et al. (13 more authors) (2024) Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials. Arthritis Research & Therapy, 26 (1). 49. ISSN 1478-6354

Simpson, E.L., Blauvelt, A., Silverberg, J.I. et al. (5 more authors) (2024) Tralokinumab provides clinically meaningful responses at week 16 in adults with moderate-to-severe atopic dermatitis who do not achieve IGA 0/1. American Journal of Clinical Dermatology, 25. pp. 139-148. ISSN 1175-0561

Blauvelt, A., Guttman-Yassky, E., Paller, A.S. et al. (13 more authors) (2022) Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis : results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE). American Journal of Clinical Dermatology, 23 (3). pp. 365-383. ISSN 1175-0561

Paller, A.S., Beck, L.A., Blauvelt, A. et al. (9 more authors) (2022) Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis—a pooled analysis of trial data. Pediatric Dermatology, 39 (2). pp. 187-196. ISSN 0736-8046

Wollenberg, A., Blauvelt, A., Guttman‐Yassky, E. et al. (19 more authors) (2021) Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2). British Journal of Dermatology, 184 (3). pp. 437-449. ISSN 0007-0963

Akinlade, B., Guttman-Yassky, E., de Bruin-Weller, M. et al. (25 more authors) (2019) Conjunctivitis in dupilumab clinical trials. British Journal of Dermatology, 181 (3). pp. 459-473. ISSN 0007-0963

Simpson, E.L., Bieber, T., Guttman-Yassky, E. et al. (23 more authors) (2016) Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. The New England Journal of Medicine. ISSN 0028-4793

Proceedings Paper

Cork, M.J. orcid.org/0000-0003-4428-2428, Eichenfield, L.F., Blauvelt, A. et al. (9 more authors) (2019) 605 Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis. In: Journal of Investigative Dermatology. Society for Investigative Dermatology (SID) 2019, 08-11 May 2019, Hilton Chicago, Chicago, Illinois. Elsevier , S104-S104.